Early and Adequate Protein Feeding Post-Traumatic Injury
Completed · Early Phase 1
Conditions studied: Protein Feeding in Post-traumatic Injury Patients
In brief
A randomized, parallel-group, pilot study comparing the effect of the early addition of intravenous protein to enteral feeding as tolerated versus enteral feedings as tolerated alone immediately post traumatic injury. Primary: To determine that early and adequate nutritional support will improve protein economy in the first week post -injury as measured by nitrogen balance. We hypothesize that an improvement in nitrogen balance with early maximized protein intake will support the production of acute phase proteins, major antioxidants and the inflammatory response. Secondary: Through the use of mass spectrometry (MS) and nuclear magnetic resonance (NMR) technologies we will determine that our plan for early and adequate nutritional support with adequate protein from day one post injury will alter the metabolomics profile when compared to routine nutritional support. Tertiary: For Specific Aim 3 we will measure several pro- and anti-inflammatory cytokines and soluble proteins.
Key facts
- Study ID
- NCT02837861
- Run by
- Boston Medical Center
- People needed
- 45
- Starts
- 2017-03-07
- Expected to finish
- 2019-10-18
- Last updated by the study team
- 2020-10-27
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Trauma Patient /Male or female, any race/ethnicity
- Expected to survive 72 hours
- Admitted to the SICU
- Expected to remain in the hospital for at least 7 days
- Candidates for enteral nutrition post-injury
You may not qualify if…
- BMI less than 18 mg/m2 or greater than 35 mg/m2
- Immunosuppressive disorders (i.e. Prednisone >20mg daily; Organ Transplant Recipient with active immunosuppression treatments, diagnosis of HIV/AIDS).
- Type I or Type II Diabetes
- Pregnancy
- Pre-existing renal dysfunction (creatinine >2.5mg/dL).
- Clear contraindication for enteral nutrition immediately post injury
- Severe liver dysfunction (Total Bilirubin > 3.0mg%)
- Non-English speaking patients
- Known allergies to any of the study drug's components
Where it is running
- Boston Medical Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.